AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

08 Aug 2024 06:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

26 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

14 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

31 May 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

17 May 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

14 May 2024 09:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

13 May 2024 06:00:00 By Nasdaq GlobeNewswire

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

24 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

23 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

02 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces Changes to its Board of Directors

01 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

14 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

12 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in Blood Cancer Journal

11 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

29 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in Nature Communications 

22 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Announces Pricing of Underwritten Offering

08 Feb 2024 06:00:46 By Nasdaq GlobeNewswire

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  

08 Feb 2024 04:45:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in ACS Chemical Biology

23 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

22 Jan 2024 06:00:00 By Nasdaq GlobeNewswire